By Professor David Goldstein

Journal articles

Chan DL; Goldstein D; Zalcberg JR, 2015, 'Neuroendocrine tumours - Models for rare tumour management', Cancer Forum, 39, pp. 13 - 16

Goldstein D; El-Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Tabernero J; Teixeira L; Tortora G; Van Laethem JL; Young R; Penenberg DN; Lu B; Romano A; Von Hoff DD, 2015, 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: Long-term survival from a phase III trial', Journal of the National Cancer Institute, 107, http://dx.doi.org/10.1093/jnci/dju413

Murphy C; Sabesan S; Steer C; Yates P; Booms A; Jones V; Simpson A; Clarke K; Eek R; Ashley D; Goldstein D; Packer C; Tuthill F; Boyce A; Underhill C, 2015, 'Oncology service initiatives and research in regional Australia', Australian Journal of Rural Health, 23, pp. 40 - 48, http://dx.doi.org/10.1111/ajr.12173

Wang X; Batty KM; Crowe PJ; Goldstein D; Yang JL, 2015, 'The Potential of panHER Inhibition in Cancer', Frontiers in Oncology, 5, pp. 2, http://dx.doi.org/10.3389/fonc.2015.00002

Pavlakis N; Sjoquist KM; Tsobanis E; Martin A; Kang Y-K; Bang Y-J; O'Callaghan CJ; Tebbutt NC; Rha SY; Lee J; Cho JY; Lipton LR; Burnell MJ; Alcindor T; Strickland A; Wong M; Kim JW; Simes J; Zalcberg JR; Goldstein D, 2015, 'INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)-A study by the Australasian Gastrointestinal Trials Group (AGITG), first results', JOURNAL OF CLINICAL ONCOLOGY, 33, http://dx.doi.org/10.1200/jco.2015.33.3_suppl.9

Vernerey D; Hammel P; Paget-Bailly S; Huguet F; Van Laethem JL; Goldstein D; Glimelius B; Artru P; Moore MJ; André T; Mineur L; Chibaudel B; Louvet C; Bonnetain F, 2015, 'Prognosis model for overall survival in locally advanced unresecable pancreatic carcinoma: An ancillary study of the LAP 07 trial.', Journal of Clinical Oncology, 33, pp. 235 - 235, http://dx.doi.org/10.1200/jco.2015.33.3_suppl.235

Kunzmann V; Ramanathan RK; Goldstein D; Penenberg DN; Ferrara S; Lu B; Von Hoff DD, 2015, 'Tumor reduction in pancreatic versus metastatic sites in a randomized phase III study (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.', Journal of Clinical Oncology, 33, pp. 382 - 382, http://dx.doi.org/10.1200/jco.2015.33.3_suppl.382

Tabernero J; Gabrielachiorean E; Infante JR; Hingorani SR; Ganju V; Weekes C; Scheithauer W; Ramanathan RK; Goldstein D; Penenberg DN; Romano A; Ferrara S; Von Hoff DD, 2015, 'Prognostic factorsofsurvival inarandomizedphaseIIItrial (MPACT)of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer', Oncologist, 20, pp. 143 - 150, http://dx.doi.org/10.1634/theoncologist.2014-0394

Vajdic CM; Goldstein D, 2015, 'Cancer of unknown primary site', Australian Family Physician, 44, pp. 640 - 643

Burmeister EA; O'Connell DL; Beesley VL; Goldstein D; Gooden HM; Janda M; Jordan SJ; Merrett ND; Payne ME; Wyld D; Neale RE, 2015, 'Describing patterns of care in pancreatic cancer a population-based study', Pancreas, 44, pp. 1259 - 1265, http://dx.doi.org/10.1097/MPA.0000000000000384

McCarroll JA; Sharbeen G; Liu J; Youkhana J; Goldstein D; McCarthy N; Limbri LF; Dischl D; Ceyhan GO; Erkan M; Johns AL; Biankin AV; Kavallaris M; Phillips PA; Johns A, 2015, 'βIII-Tubulin: A novel mediator of chemoresistance and metastases in pancreatic cancer', Oncotarget, 6, pp. 2235 - 2249, http://dx.doi.org/10.18632/oncotarget.2946

Neale R; Burmeister E; O'Connell D; Beesley V; Goldstein D; Gooden H; Janda M; Jordan S; Merrett N; Payne M; Wyld D, 2015, 'Describing patterns of care in pancreatic cancer – A population-based study', Pancreatology, 15, pp. S83 - S83, http://dx.doi.org/10.1016/j.pan.2015.05.306

Burmeister E; Jordan S; O'Connell D; Beesley V; Goldstein D; Gooden H; Janda M; Merrett N; Wyld D; Neale R, 2015, 'Determinants of attempted resection for patients with non-metastatic pancreatic cancer', Pancreatology, 15, pp. S84 - S85, http://dx.doi.org/10.1016/j.pan.2015.05.312

Neale R; Waterhouse M; Burmeister E; Ballard E; O'Connell D; Beesley V; Goldstein D; Gooden H; Janda M; Jordan S; Merrett N; Payne M; Wyld D, 2015, 'Determinants of outcomes following resection for pancreatic cancer – An Australian population-based study', Pancreatology, 15, pp. S85 - S85, http://dx.doi.org/10.1016/j.pan.2015.05.313

Pavlakis N; Sjoquist KM; Tsobanis E; Martin AJ; Kang Y-K; Bang Y-J; O'Callaghan CJ; Tebbutt NC; Rha SY; Lee J; Cho JY; Lipton LR; Burnell MJ; Alcindor T; Strickland A; Kim JW; Yip S; Simes J; Zalcberg JR; Goldstein D, 2015, 'LBA-06 INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib (REG) in refractory advanced oesophagogastric cancer (AOGC) - A study by the Australasian Gastrointestinal Trials Group (AGITG): Final overall and subgroup results', Annals of Oncology, 26, pp. iv119 - iv119, http://dx.doi.org/10.1093/annonc/mdv262.06

Tempero M; Cardin D; Biankin A; Goldstein D; Moore M; O'Reilly E; Philip P; Riess H; Macarulla T; Yung L; Li M; Lu B, 2015, 'P-185 Randomized phase III trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant therapy for patients with resected pancreatic cancer: APACT', Annals of Oncology, 26, pp. iv54 - iv54, http://dx.doi.org/10.1093/annonc/mdv233.185

Vernerey D; Goldstein D; Huguet F; Paget-Bailly S; Van Laethem J-L; Glimelius B; Artru P; Moore MJ; André T; Mineur L; Chibaudel B; Louvet C; Hammel P; Bonnetain F, 2015, 'Prognostic score and nomogram to predict overall survival in locally advanced pancreatic cancer', Pancreatology, 15, pp. S107 - S107, http://dx.doi.org/10.1016/j.pan.2015.05.383

Goldstein D; Giver M; Chakraborty B, 2015, 'Synchronization patterns in geometrically frustrated rings of relaxation oscillators.', Chaos, 25, pp. 123109, http://dx.doi.org/10.1063/1.4936246

Tempero M; Cardin D; Biankin AV; Goldstein D; Moore M; O'Reilly E; Philip P; Riess H; Macarulla T; Yung L; Li M; Lu B, 2015, 'Tu1953 Nab-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone for Resected Pancreatic Cancer in a Phase III Trial (APACT)', Gastroenterology, 148, pp. S - 944, http://dx.doi.org/10.1016/s0016-5085(15)33220-0

Park SB; Kwok JB; Loy CT; Friedlander ML; Lin CSY; Krishnan AV; Lewis CR; Kiernan MC; Goldstein D, 2014, 'Paclitaxel-induced neuropathy: Potential association of MAPT and GSK3B genotypes', BMC Cancer, 14, pp. 993, http://dx.doi.org/10.1186/1471-2407-14-993

McGrane JA; Butow PN; Sze M; Eisenbruch M; Goldstein D; King MT, 2014, 'Assessing the invariance of a culturally competent multi-lingual unmet needs survey for immigrant and Australian-born cancer patients: a Rasch analysis', Quality of Life Research, 23, pp. 2819 - 2830, http://dx.doi.org/10.1007/s11136-014-0717-5

Jefford M; Nolte L; Tsintziras S; Butow P; Sze M; Yiu D; Schofield P; Goldstein D; Price M, 2014, 'HOW IS POST-TREATMENT SURVIVORSHIP CONCEPTUALISED BY PEOPLE FROM DIFFERENT CULTURAL GROUPS?', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 10, pp. 158 - 158, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000346343700480&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wang X; Goldstein D; Crowe PJ; Yang JL, 2014, 'Impact of STAT3 inhibition on survival of osteosarcoma cell lines', Anticancer Research, 34, pp. 6537 - 6545

McGrane J; Butow P; Sze M; Eisenbruch M; Goldstein D; King M, 2014, 'Assessing the Invariance of a Culturally Competent Multi-lingual Unmet Needs Survey for Immigrant and Australian-born Cancer Patients: A Rasch Analysis', PSYCHO-ONCOLOGY, 23, pp. 153 - 153, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344003700220&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hillman RJ; Garland SM; Gunathilake MPW; Stevens M; Kumaradevan N; Lemech C; Ward RL; Meagher A; McHugh L; Jin F; Carroll S; Goldstein D; Grulich AE; Tabrizi SN, 2014, 'Human papillomavirus (HPV) genotypes in an Australian sample of anal cancers', International Journal of Cancer, 135, pp. 996 - 1001, http://dx.doi.org/10.1002/ijc.28730

Vernerey D; Hammel P; Paget-Bailly S; Huguet F; Van Laethem JL; Goldstein D; Glimelius B; Artru P; Moore M; André T; Mineur L; Chibaudel B; Louvet C; Bonnetain F, 2014, 'Prognosis Model for Overall Survival in Locally Advanced Pancreatic Cancer (LAPC): An Ancillary Study of the Lap 07 Trial', Annals of Oncology, 25, pp. ii105, http://dx.doi.org/10.1093/annonc/mdu193.2

McGrane JA; Butow PN; Sze M; Eisenbruch M; Goldstein D; King MT, 2014, 'Assessing the invariance of a culturally competent multi-lingual unmet needs survey for immigrant and Australian-born cancer patients: a Rasch analysis', Quality of Life Research, http://dx.doi.org/10.1007/s11136-014-0717-5

Sears K; Broderick B; Goldstein D; Stockley D, 2014, 'The Development of a New Master’s of Science in Healthcare Quality Program', Collected Essays on Learning and Teaching, 7, pp. 39 - 45, http://dx.doi.org/10.22329/celt.v7i1.3991

Goldstein D; EI-Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Macarulla T; Teixeira L; Tortora G; Van Laethem JL; Penenberg DN; Lu B; Romano A; Von Hoff DD, 2014, 'Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC).', JOURNAL OF CLINICAL ONCOLOGY, 32, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.4027

Tempero MA; Cardin DB; Biankin A; Goldstein D; Moore M; O'Reilly EM; Philip PA; Riess H; Macarulla T; Yung L; Wei X; Lu B, 2014, 'APACT: A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with surgically resected ductal pancreatic adenocarcinoma (PDA).', Journal of Clinical Oncology, 32, pp. TPS4162 - TPS4162, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.tps4162

Reichardt P; Demetri GD; Gelderblom H; Rutkowski P; Im S-A; Gupta S; Kang Y-K; Schoffski P; Schuette J; Soulieres D; Blay J-Y; Goldstein D; Fly KD; Huang X; Corsaro M; Lechuga M; Martini J-F; Heinrich MC, 2014, 'Correlation of KIT and PDGFRA mutational status with clinical benefit in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU) in a worldwide treatment-use (TU) trial.', JOURNAL OF CLINICAL ONCOLOGY, 32, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.10549

Huguet F; Hammel P; Vernerey D; Goldstein D; Van Laethem JL; Glimelius B; Spry N; Paget-Bailly S; Bonnetain F; Louvet C, 2014, 'Impact of chemoradiotherapy (CRT) on local control and time without treatment in patients with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07 study.', Journal of Clinical Oncology, 32, pp. 4001 - 4001, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.4001

Vernerey D; Hammel P; Paget-Bailly S; Huguet F; Van Laethem JL; Goldstein D; Glimelius B; Artru P; Moore M; André T; Mineur L; Chibaudel B; Louvet C; Bonnetain F, 2014, 'Prognosis model for overall survival in locally advanced pancreatic cancer (LAPC): An ancillary study of the LAP 07 trial.', Journal of Clinical Oncology, 32, pp. 4024 - 4024, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.4024

Davis ID; Long A; Martin A; Espinoza D; Yip S; Thompson JF; Kichenadasse G; Harrison M; Lowenthal RM; Pavlakis N; Azad A; Kannourakis G; Steer C; Goldstein D; Shapiro J; Stockler MR, 2014, 'EVERSUN: A PHASE 2 TRIAL OF EVEROLIMUS ALTERNATING WITH SUNITINIB AS FIRST-LINE THERAPY FOR ADVANCED RENAL CELL CARCINOMA (ANZUP TRIAL 0901)', EUROPEAN JOURNAL OF CANCER, 50, pp. E68 - E69, http://dx.doi.org/10.1016/j.ejca.2014.03.255

Valle JW; Palmer D; Jackson R; Cox T; Neoptolemos JP; Ghaneh P; Rawcliffe CL; Bassi C; Stocken DD; Cunningham D; O'Reilly D; Goldstein D; Robinson BA; Karapetis C; Scarfe A; Lacaine F; Sand J; Izbicki JR; Mayerle J; Dervenis C; Oláh A; Butturini G; Lind PA; Middleton MR; Anthoney A; Sumpter K; Carter R; Büchler MW, 2014, 'Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: Ongoing lessons from the ESPAC-3 study', Journal of Clinical Oncology, 32, pp. 504 - 512, http://dx.doi.org/10.1200/JCO.2013.50.7657

Ramanathan RK; Von Hoff DD; Moore MJ; Teixeira L; Siena S; Tabernero J; Goldstein D; Wei X; Lu B, 2014, 'Analysis of metabolic response (MR) by positron emission tomography (PET) compared with tumor response by computed tomography (CT) from MPACT, a phase III trial comparing nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone for patients (pts) with metastatic adenocarcinoma of the pancreas', JOURNAL OF CLINICAL ONCOLOGY, 32, http://dx.doi.org/10.1200/jco.2014.32.3_suppl.254

Goldstein D; El Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Tabernero J; Teixeira L; Tortora G; Van Laethem J-L; Young R; Wei X; Lu B; Romano A; Von Hoff DD, 2014, 'Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas', JOURNAL OF CLINICAL ONCOLOGY, 32, http://dx.doi.org/10.1200/jco.2014.32.3_suppl.178

Bennett BK; Goldstein D; Chen M; Davenport TA; Vollmer-Conna U; Scott EM; Hickie IB; Lloyd AR, 2014, 'Characterization of fatigue states in medicine and psychiatry by structured interview', Psychosomatic Medicine, 76, pp. 379 - 388, http://dx.doi.org/10.1097/PSY.0000000000000061

Goldstein D; Bell ML; Butow P; Sze M; Vaccaro L; Dong S; Liauw W; Hui R; Tattersall M; Ng W; Asghari R; Steer C; Vardy J; Parente P; Harris M; Karanth NV; King M; Girgis A; Eisenbruch M; Jefford M, 2014, 'Immigrants' perceptions of the quality of their cancer care: An Australian comparative study, identifying potentially modifiable factors', Annals of Oncology, 25, pp. 1643 - 1649, http://dx.doi.org/10.1093/annonc/mdu182

Greenhalf W; Ghaneh P; Neoptolemos JP; Palmer DH; Cox TF; Lamb RF; Garner E; Campbell F; MacKey JR; Costello E; Moore MJ; Valle JW; McDonald AC; Carter R; Tebbutt NC; Goldstein D; Shannon J; Dervenis C; Glimelius B; Deakin M; Charnley RM; Lacaine F; Scarfe AG; Middleton MR; Anthoney A; Halloran CM; Mayerle J; Oláh A; Jackson R; Rawcliffe CL; Scarpa A; Bassi C; Büchler MW, 2014, 'Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial', Journal of the National Cancer Institute, 106, http://dx.doi.org/10.1093/jnci/djt347

McCarroll JA; Naim S; Sharbeen G; Russia N; Lee J; Kavallaris M; Goldstein D; Phillips PA, 2014, 'Role of pancreatic stellate cells in chemoresistance in pancreatic cancer', Frontiers in Physiology, 5 APR, pp. 141, http://dx.doi.org/10.3389/fphys.2014.00141

Von Hoff DD; Goldstein D; Renschler MF, 2014, 'The authors reply', New England Journal of Medicine, 370, pp. 479 - 480, http://dx.doi.org/10.1056/NEJMc1314761

Patel MB; Pothula SP; Xu Z; Lee AK; Goldstein D; Pirola RC; Apte MV; Wilson JS, 2014, 'The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: Anti-angiogenic implications in pancreatic cancer', Carcinogenesis, 35, http://dx.doi.org/10.1093/carcin/bgu122

Murray JE; Pickering HR; Lin CS-Y; Goldstein D; Friedlander ML; Kiernan MC; Krishnan AV, 2014, '6. Functional impact of neuropathy in patients receiving oxaliplatin chemotherapy', Clinical Neurophysiology, 125, pp. e3 - e3, http://dx.doi.org/10.1016/j.clinph.2013.10.028

Tempero M; Cardin D; Biankin A; Goldstein D; Moore M; O’Reilly E; Philip P; Riess H; Macarulla T; Yung L; Wei X; Lu B, 2014, 'APACT: A Phase III Trial of Nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) Versus Gem Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (PC)', American Journal of Gastroenterology, 109, pp. S72 - S72, http://dx.doi.org/10.14309/00000434-201410002-00232

Tempero MA; Cardin D; Biankin A; Goldstein D; Moore M; O'Reilly EM; Philip PA; Riess H; Macarulla T; Yung L; Wei X; Lu B, 2014, 'Apact: a Phase III Trial of Nab-Paclitaxel (Nab-P) Plus Gemcitabine (Gem) Vs Gem Alone for Resected Pancreatic Cancer (Pc)', Annals of Oncology, 25, pp. iv252 - iv252, http://dx.doi.org/10.1093/annonc/mdu334.131

Huguet F; Hammel P; Vernerey D; Van Laethem J; Goldstein D; Glimelius B; Bonnetain F; Louvet C, 2014, 'Impact de la chimioradiothérapie sur le contrôle local et le temps sans traitement dans l’essai de phase III LAP07', Cancer/Radiothérapie, 18, pp. 587 - 587, http://dx.doi.org/10.1016/j.canrad.2014.07.013

Hammel P; Huguet F; Dewi V; Laethem J-LV; Goldstein D; Glimelius B; Artru P; Borbath Y; Bonnetain F; Louvet C, 2014, 'Impact of chemoradiotherapy (CRT) on local tumour control and time without treatment in patients with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07 study', Pancreatology, 14, pp. S6 - S6, http://dx.doi.org/10.1016/j.pan.2014.05.398

McCarroll J; Teo J; Boyer C; Goldstein D; Kavallaris M; Phillips PA, 2014, 'Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer', Frontiers in Physiology, 5, pp. 1 - 10, http://dx.doi.org/10.3389/fphys.2014.00002

Siena S; Lipton L; Letourneau R; Tjulandin SA; Guillen Ponce C; Schwarz M; Ramanathan RK; Macarulla T; Goldstein D; Romano A; Ferrara S; Penenberg D; Von Hoff DD, 2014, 'Regional Subanalysis of the Phase III Mpact Trial: Nab-Paclitaxel (Nab-P) Plus Gemcitabine (Gem) Vs Gem Alone for Patients (Pts) with Metastatic Pancreatic Cancer (Pc)', Annals of Oncology, 25, pp. iv235 - iv235, http://dx.doi.org/10.1093/annonc/mdu334.76

Back to profile page